Back to search
FDAFDA · Food and drugs·Recall number D-0375-2019

Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Published January 16, 2019 · Recall initiated: January 2, 2019

Summary

FDA records drug Class II recall D-0375-2019, published January 16, 2019 and initiated January 2, 2019. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 287,784 bottles; Lot: a) Lot #: F700329, F700330, F700328, Exp. January 2019; F700544, F700545, F700668, F700669, F700670, Exp. March 2019; F700958, Exp. April 2019 b) Lot #: F700327, F700392, F700393, Exp. January 2019; F700546, F700547, F700664, Exp. March 2019; F700967, Exp. April 2019, F701106, F701107, F701108, F701109, Exp. May 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

What to do

Voluntary: Firm initiated · Letter

Get an email if CEFDINIR has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CEFDINIR
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide within the United States
UPC
0368180723042
Lot
a) Lot #: F700329, F700330, F700328, Exp. January 2019; F700544, F700545, F700668, F700669, F700670, Exp. March 2019; F700958, Exp. April 2019 b) Lot #: F700327, F700392, F700393, Exp. January 2019; F700546, F700547, F700664, Exp. March 2019; F700967, Exp. April 2019, F701106, F701107, F701108, F701109, Exp. May 2019.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA recalled?

Yes. FDA published recall D-0375-2019 on January 16, 2019. Reported hazard: CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CEFDINIR. UPC: 0368180723042.